Analysis of real-world data on overall survival in multiple myeloma patients with ³3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD

Oncologist

Volumn 21, Issue 11, 2016, Pages 1355-1361

  Usmani, Saad ^a   Ahmadi, Tahamtan ^b   Ng, Yvette ^c   Lam, Annette ^c   Desai, Avinash ^c   Potluri, Ravi ^d   Mehra, Maneesha ^c  

^a Levine Cancer Institute   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d SmartAnalyst   (United States)

Author keywords

Electronic health records; Multiple myeloma; Retrospective studies; Survival analysis

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISOLONE; PREDNISONE; THALIDOMIDE; VINCRISTINE; VORINOSTAT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; DISEASE COURSE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84995370793     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0104     Document Type: Article

References (22)

1. Harousseau JL. Ten years of improvement in the management of multiplemyeloma: 2000-2010. Clin Lymphoma Myeloma Leuk 2010;10:424-442.
2. Kastritis E, Zervas K, Symeonidis A et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS):Ananalysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009;23:1152-1157.
3. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
4. Lee HC, Shah JJ, Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book 2013;2013: e302-e306.
5. Meadows JP, Mark TM. Management of doublerefractory multiple myeloma. Curr Hematol Malig Rep 2013;8:253-260.
6. van de Donk NW, Lokhorst HM. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother 2013;14: 1569-1573.
7. Kumar SK, Lee JH, Lahuerta JJ et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study. Leukemia 2012;26:149-157.
8. Elkinson S, McCormack PL. Pomalidomide: First global approval. Drugs 2013;73:595-604.
9. McCormack PL. Carfilzomib: In relapsed, or relapsed and refractory, multiple myeloma. Drugs 2012;72:2023-2032.
10. San Miguel J, Weisel K, Moreau P et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:1055-1066.
11. Dimopoulos MA, Weisel KC, Song KW et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and lowdose dexamethasone. Haematologica 2015;100: 1327-1333.
12. Ludwig H, Masszi T, Petrucci MT et al. Carfilzomib (K) vs low-dose corticosteroids and optional cyclophosphamide (Cy) in patients (pts) with relapsed and refractory multiple myeloma (RRMM): Results from a phase 3 study (FOCUS). Ann Oncol 2014;25 (suppl 4). doi: 10.1093/annonc/mdu438.29
13. Turesson I, Velez R, Kristinsson SY et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a populationbased study. J Clin Oncol 2010;28:830-834.
14. Turesson I, Abildgaard N, Ahlgren T et al. Prognostic evaluation in multiple myeloma: An analysis of the impact of new prognostic factors. Br J Haematol 1999;106:1005-1012.
15. Richardson PG, Siegel DS, Vij R et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study. Blood 2014; 123:1826-1832.
16. Siegel DS, Martin T, Wang M et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-2825.
17. Rajkumar SV, Kumar S. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc 2016;91: 101-119.
18. Lonial S, Weiss BM, Usmani SZ et al. Daratumumab monotherapy in patients with treatment refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet 2016;387:1551-1560.
19. Lin P, Owens R, Tricot G et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482-488.
20. Santonocito AM, Consoli U, Bagnato S et al. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res 2004;28: 469-477.
21. Deaglio S, Mehta K, Malavasi F. Human CD 38: A (r)evolutionary story of enzymes and receptors. Leuk Res 2001;25:1-12.
22. Usmani S, Ahmadi T, Ng Y et al. Analyses of real world data on overall survival in multiple myeloma patients with at least 3 prior lines of therapy including a PI and an IMiD, or double refractory to a PI and an IMiD. Blood 2015;126:4498.